Spinal Muscular Atrophy Trial, Recruiting (NCT06152302)

Spinal Muscular Atrophy Trial, Recruiting NCT06152302 Sponsor: Assistance Publique - Hôpitaux de Paris Condition: Spinal Muscular Atrophy

Printed from Voxsanity (voxsanity.com.au) — NCT06152302 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Spinal Muscular Atrophy

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

The child must be an infant with muscle weakness (sometimes called a "floppy baby") who has been officially diagnosed with Spinal Muscular Atrophy (SMA) through a genetic test showing a change or missing section in the SMN1 gene.
The child must be receiving standard medical care for their condition.
The child must be under 12 years old and shorter than 90 cm at the time of joining the trial.
The child must be enrolled in a social security (health insurance) scheme.
Both parents of the child must give their written consent to participate, along with the agreement of the medical professional running the trial.

Who may not be able to join:

Children who have injuries or damage to their spinal cord, or who have conditions affecting their heart or breathing system.
Children who are covered under the French Aid in Health for Foreign People program (known as AME).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Susana Quijano-Roy, MD, PhD, Paediatric neurological and intentive care unity, Raymond Poincaré Hospital - APHP

Phone: + 33 1 47 10 78 90

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06152302

Sponsor: Assistance Publique - Hôpitaux de Paris

Phase: Not Applicable

Status: Recruiting

Condition: Spinal Muscular Atrophy

Trial contact: + 33 1 47 10 78 90

More information: https://clinicaltrials.gov/study/NCT06152302

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

The child must be an infant with muscle weakness (sometimes called a "floppy baby") who has been officially diagnosed with Spinal Muscular Atrophy (SMA) through a genetic test showing a change or missing section in the SMN1 gene.
The child must be receiving standard medical care for their condition.
The child must be under 12 years old and shorter than 90 cm at the time of joining the trial.
The child must be enrolled in a social security (health insurance) scheme.
Both parents of the child must give their written consent to participate, along with the agreement of the medical professional running the trial.

Who may not be able to join:

Children who have injuries or damage to their spinal cord, or who have conditions affecting their heart or breathing system.
Children who are covered under the French Aid in Health for Foreign People program (known as AME).

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Assistance Publique - Hôpitaux de Paris

Registry

ClinicalTrials.gov

Start date

26 June 2025

Est. completion

1 June 2026

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Delta of 95th percentile of free acceleration norm (in m/s²)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov